<DOC>
	<DOC>NCT00991744</DOC>
	<brief_summary>- Replacement of intrathecal Triple (methotrexate, cytarabine, prednisolone) with intrathecal liposomal cytarabine and prednisolone during maintenance therapy will decrease the CNS relapse rate in high-risk ALL patients. - Both acute and long-term toxicity are equal in both treatment arms.</brief_summary>
	<brief_title>Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL)</brief_title>
	<detailed_description>20% of children with ALL still fails to be cured. The ALL-2008 protocol is a treatment and research protocol that aims to improve the overall outcome of Nordic children and adolescents with ALL in comparison with the ALL-2000 protocol and previous NOPHO protocols. The specific and primary objectives of the randomised study is: 1. To replace intrathecal triple (methotrexate, cytarabine and glucocorticosteroid) by intrathecal liposomal cytarabine and glucocorticosteroid during maintenance therapy in order to decrease the central nervous system relapse rate in high-risk acute lymphoblastic leukemia patients. 2. To evaluate acute and long-term toxicity in both treatment arms.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>High risk acute lymphoblastic leukemia Not eligible for bone marrow transplantation Age 118 Written informed consent has been obtained Persistent NCI grade 34 neurotoxicity from previous treatments Bilineage ALL Leukemia predisposing syndromes (e.g. Downs syndrome, Ataxia Telangiectasia) Previous cancer Known intolerance to NOPHO ALL 2008 anticancer agents Sexually active females will use safe contraceptives Previous treatment with intrathecal liposomal cytarabine</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Central nervous system</keyword>
	<keyword>Neurotoxicity</keyword>
	<keyword>Liposomal cytarabine</keyword>
	<keyword>Children</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>Childhood acute lymphoblastic leukemia</keyword>
	<keyword>Intrathecal</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
</DOC>